UUAB - Uppsala universitets Utveckling AB

Validera

Veprox Medical

Visipower

World Courier (Sweden) AB

YIT Sverige AB

Novo Nordisk to invest billions in Danish manufacturing facilities

Danish pharmaceutical giant Novo Nordisk is investing DKK 42 billion, equivalent to around SEK 65 billion/EUR 5.6 billion, in its manufacturing facilities in Ka...

Ingrid Lönnstedt: What does the p-value mean?

The smaller the better, and preferably smaller than 0.05. A p-value smaller than 5% means that the treatment effect is statistically significant at 5% significa...

Mathias Uhlén’s protein atlas is recognised as a global resource

The Human Protein Atlas is the first database in Sweden to be designated a Global Core Biodata Resource. According to Mathias Uhlén, this is a quality hallmark ...

Medeon AB

Heidi Stensmyren is eager for new challenges in the biotech industry

Heidi Stensmyren has served as President of the Swedish Medical Association, held a managerial position at Karolinska University Hospital and is now Medical Dir...

Anna Törner: The clinical trial – Periscope to reality

What happens to the patients in the clinical trial is not very interesting, writes Anna Törner in a column.

Charlotta Gummeson leaves Sahlgrenska Science Park – “It feels sad and exciting at the same time”

forward and thinking about all the new things that there will be in a freer role,” she says to Life Science Sweden

The first drugs to slow down Alzheimer’s – but what does it mean for patients?

New treatments for early Alzheimer’s are bringing hope to thousands of patients and their families. The question is, who will get the treatment, how will the ri...

Webinar: How to Plan And Analyze a Real-World Evidence Study

This webinar is for drug developers who want to understand the basic ideas of analyzing an RWE study, as well as avoiding the most common pitfalls.

Egetis bekräftar budsamtal

Den svenska läkemedelsutvecklaren Egetis Therapeutics för diskussioner om ett potentiellt bud på bolaget. Det bekräftar företaget i en kommentar till ihärdiga r...

Nässprej för behandling av anafylaxi godkänd i USA

Den amerikanska läkemedelsmyndigheten, FDA, har gett tummen upp till en ny typ av nässprej. Nässprejen är ett injektionsfritt alternativ för behandling av akuta...

Ännu ett genterapibolag krisar – säger upp 100

Det är tuffa tider för många cell- och genterapibolag. Det senaste exemplet är amerikanska Bluebird Bio, som säger upp var fjärde anställd i ett försök att rädda verksamheten.

Samuel Lagercrantz: The government’s performance in healthcare and life sciences so far

Since the change of government in Sweden, developments in the healthcare sector have shown promising signs, but the outlook in life sciences is less promising, ...

“A major energy boost for the entire cancer vaccine field”

The development of cancer vaccines has accelerated in recent years. Norwegian Ultimovacs is one of the companies attempting to develop a new type of treatment l...

EU Pharmaceutical Legislation Reform

The EU's Pharmaceutical Legislation Reform, proposed by the commission within the European Health Union, aims to establish a citizen-centric framework to enhanc...

On the hunt for high throughput diagnostics

Global diagnostics companies and laboratories are in a race against time to adapt testing capacity to current demand. Due to the global COVID 19 pandemic, the d...

Bilden av Alzheimers – neurobiolog vid SU och KI får Lennart Nilssons pris

Med fascinerande bilder och filmer i 3D har han bidragit till ökad kunskap om allt från innerörats anatomi till sjukdomar som fettlever och Alzheimers. Nu tilld...

Egetis lägger ned buddiskussionerna

Svenska läkemedelsutvecklaren Egetis Therapeutics har gått ut med att diskussionerna om ett potentiellt förvärv av företaget nu har lagts ner.